PDF herunterladen
CC BY 4.0 · World J Nucl Med
DOI: 10.1055/s-0045-1806800
Original Article

Locoregional Recurrence after Biochemical Incomplete Response in Differentiated Thyroid Cancer Patients: Insights into Influencing Clinicopathological Factors and the Potential Role of 18F-FDG PET/CT

Mai Amr Elahmadawy 
1   Nuclear Medicine Unit, National Cancer Institute (NCI), Cairo University, Cairo, Egypt
,
Ismail Mohamed Ali
2   Radiodiagnosis Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
,
Ibrahim Mansour Nasr
3   Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
,
Omnia Talaat
1   Nuclear Medicine Unit, National Cancer Institute (NCI), Cairo University, Cairo, Egypt
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Objective

The aim of this study was to evaluate the clinicopathological factors and stimulated thyroglobulin (Tg) course related to the occurrence of locoregional recurrence (LRR) in differentiated thyroid cancer (DTC) patients with biochemical incomplete response (BIR) as well as the value of fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) in these patients.

Methods

A total of 253 DTC adult patients initially treated with total thyroidectomy and iodine-131 (RAI-131) ablation and showed BIR on follow-up were enrolled in the study. All clinical, laboratory, pathological, radiological, and follow-up data were retrieved from their records.

Results

Seventy-three out of the 253 BIR patients developed LRR during follow-up with the median time to recurrence of 27 months. In all, 61.6% of those who developed LRR were females, 78.1% were papillary thyroid carcinomas, 35.6% had initial regional nodal deposits, and the primary tumors were T2 and T3 in 78.2% of these patients (p < 0.05). The median Tg level for those who developed LRR compared with those who remained free was 18 versus 17 ng/mL, respectively, at 6 months of follow-up. Meanwhile, on further 1-year follow-up, the median value spontaneously increased for the positive group to 37.6 ng/mL and decreased for those who remained free to 3 ng/mL. Eighty percent of the patients with a rising course of Tg level developed structural LRR (p < 0.001). 18F-FDG PET/CT showed the highest sensitivity and negative predictive value (NPV) of 100% in the detection of LRR compared with sensitivity values of 92.86 and 85.71% and NPV of 99.58 and 99.17%, respectively, with ultrasound (US) and RAI-131 scan. Meanwhile the highest specificity and positive predictive value (PPV) of 100% were observed noted with RAI-131 compared to specificity values of 99.16 and 99.58% and PPV of 87.50 and 92.86% with PET/CT and US, respectively. A cutoff point (SUVmax of 3.65) was successfully marked to discriminate those positive versus negative LRR with sensitivity and specificity of 100% and p-value of less than 0.001.

Conclusion

Structural LRR after BIR appears to be more commonly associated with worse clinicopathological parameters and the incremental Tg levels serve as an indicator of its higher incidence. 18F-FDG PET/CT has been shown to be a valuable diagnostic tool rather than a prognostic one in these patients.

Keywords

BIR - thyroid cancer - locoregional recurrence - Tg - PET/CT

Authors' Contributions

M.A.E. and I.M.N. conceived the presented idea and M.A.E. wrote the manuscript. I.M.A. helped in data interpretation. O.T. participated in the analysis and interpretation of data. All the authors revised and gave final approval of the version to be submitted.


Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.




Publikationsverlauf

Artikel online veröffentlicht:
24. März 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kim TY, Kim WG, Kim WB, Shong YK. Current status and future perspectives in differentiated thyroid cancer. Endocrinol Metab (Seoul) 2014; 29 (03) 217-225
    CrossrefPubMedSuche in Google Scholar
  • 2 Pitoia F, Jerkovich F. Dynamic risk assessment in patients with differentiated thyroid cancer. Endocr Relat Cancer 2019; 26 (10) R553-R566
    CrossrefPubMedSuche in Google Scholar
  • 3 Tuttle RM, Alzahrani AS. Risk stratification in differentiated thyroid cancer: from detection to final follow-up. J Clin Endocrinol Metab 2019; 104 (09) 4087-4100
    CrossrefPubMedSuche in Google Scholar
  • 4 Cooper DS, Doherty GM, Haugen BR. et al; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19 (11) 1167-1214
    CrossrefPubMedSuche in Google Scholar
  • 5 Pitoia F, Ward L, Wohllk N. et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 2009; 53 (07) 884-887
    CrossrefPubMedSuche in Google Scholar
  • 6 Luster M, Aktolun C, Amendoeira I. et al. European perspective on 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: proceedings of an interactive international symposium. Thyroid 2019; 29 (01) 7-26
    CrossrefPubMedSuche in Google Scholar
  • 7 Wang Y, Wu J, Jiang L, Zhang X, Liu B. Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study. Endocrine 2022; 76 (01) 109-115
    CrossrefPubMedSuche in Google Scholar
  • 8 Tuttle RM. Optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation?. Endocrine 2014; 46 (03) 363-364
    CrossrefPubMedSuche in Google Scholar
  • 9 Kukulska A, Krajewska J, Kołosza Z. et al. The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice. Eur J Endocrinol 2016; 175 (05) 379-385
    CrossrefPubMedSuche in Google Scholar
  • 10 Kim BH, Kim SJ, Kim K. et al. High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma. Ann Nucl Med 2015; 29 (08) 721-729
    CrossrefPubMedSuche in Google Scholar
  • 11 Palmedo H, Bucerius J, Joe A. et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006; 47 (04) 616-624
    PubMedSuche in Google Scholar
  • 12 Shah JP, Montero PH. New AJCC/UICC staging system for head and neck, and thyroid cancer. Rev Med Clin Las Condes 2018; 29 (04) 397-404
    Suche in Google Scholar
  • 13 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26 (01) 1-133
    CrossrefPubMedSuche in Google Scholar
  • 14 Boellaard R, Delgado-Bolton R, Oyen WJ. et al; European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42 (02) 328-354
    CrossrefPubMedSuche in Google Scholar
  • 15 Chan YH. Biostatistics 102: quantitative data—parametric & non-parametric tests. Singapore Med J 2003; 44 (08) 391-396
    PubMedSuche in Google Scholar
  • 16 Chan YH. Biostatistics 103: qualitative data: tests of independence. Singapore Med J 2003; 44 (10) 498-503
    PubMedSuche in Google Scholar
  • 17 Galen RS. Predictive value and efficiency of laboratory testing. Pediatr Clin North Am 1980; 27 (04) 861-869
    CrossrefPubMedSuche in Google Scholar
  • 18 Phan HT, Jager PL, van der Wal JE. et al. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol 2008; 158 (01) 77-83
    CrossrefPubMedSuche in Google Scholar
  • 19 Lim ST, Jeon YW, Gwak H, Bae JS, Suh YJ. Nomogram for the prediction of biochemical incomplete response in papillary thyroid cancer patients. Cancer Manag Res 2021; 13: 5641-5650
    CrossrefPubMedSuche in Google Scholar
  • 20 Vaisman F, Tala H, Grewal R, Tuttle RM. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 2011; 21 (12) 1317-1322
    CrossrefPubMedSuche in Google Scholar
  • 21 Vaisman F, Momesso D, Bulzico DA. et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf) 2012; 77 (01) 132-138
    CrossrefPubMedSuche in Google Scholar
  • 22 Pitoia F, Abelleira E, Tala H, Bueno F, Urciuoli C, Cross G. Biochemical persistence in thyroid cancer: is there anything to worry about?. Endocrine 2014; 46 (03) 532-537
    CrossrefPubMedSuche in Google Scholar
  • 23 Zern NK, Clifton-Bligh R, Gill AJ. et al. Disease progression in papillary thyroid cancer with biochemical incomplete response to initial therapy. Ann Surg Oncol 2017; 24 (09) 2611-2616
    CrossrefPubMedSuche in Google Scholar
  • 24 Ahn J, Song E, Kim WG. et al. Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response. Endocrine 2020; 67 (03) 623-629
    CrossrefPubMedSuche in Google Scholar
  • 25 Rouxel A, Hejblum G, Bernier MO. et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2004; 89 (11) 5362-5368
    CrossrefPubMedSuche in Google Scholar
  • 26 Arrangoiz R, De Llano JG, Mijares MF. et al. Current understanding of papillary thyroid carcinoma. Int J Otolaryngol Head Neck Surg 2021; 10 (03) 184-221
    CrossrefSuche in Google Scholar
  • 27 Yim JH, Kim EY, Bae Kim W. et al. Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer. Thyroid 2013; 23 (01) 58-63
    CrossrefPubMedSuche in Google Scholar
  • 28 Duren M, Siperstein AE, Shen W, Duh QY, Morita E, Clark OH. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high-and low-risk patients. Surgery 1999; 126 (01) 13-19
    CrossrefPubMedSuche in Google Scholar
  • 29 Carvalho JMG, Görlich D, Schober O. et al. Evaluation of 131 I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients. Eur J Nucl Med Mol Imaging 2017; 44: 744-756
    CrossrefPubMedSuche in Google Scholar
  • 30 Agate L, Bianchi F, Giorgetti A. et al. Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels. J Endocrinol Invest 2014; 37 (10) 967-972
    CrossrefPubMedSuche in Google Scholar
  • 31 Shalash AM, Elahmadawy MA, Heikal SY, Amin AA, Youssef AA. Value of diffusion MRI versus [18F]FDG PET/CT in detection of cervical nodal metastases in differentiated thyroid cancer patients. Nucl Med Rev Cent East Eur 2022; 25 (02) 112-118
    CrossrefPubMedSuche in Google Scholar
  • 32 Lamartina L, Deandreis D, Durante C, Filetti S. Endocrine tumours: imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. Eur J Endocrinol 2016; 175 (05) R185-R202
    CrossrefPubMedSuche in Google Scholar
  • 33 Campennì A, Barbaro D, Guzzo M, Capoccetti F, Giovanella L. Personalized management of differentiated thyroid cancer in real life: practical guidance from a multidisciplinary panel of experts. Endocrine 2020; 70 (02) 280-291
    CrossrefPubMedSuche in Google Scholar
  • 34 Qichang W, Lin B, Gege Z. et al. Diagnostic performance of 18F-FDG-PET/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis. Eur J Endocrinol 2019; 181 (02) 93-102
    CrossrefPubMedSuche in Google Scholar
  • 35 Smallridge RC, Diehl N, Bernet V. Practice trends in patients with persistent detectable thyroglobulin and negative diagnostic radioiodine whole body scans: a survey of American Thyroid Association members. Thyroid 2014; 24 (10) 1501-1507
    CrossrefPubMedSuche in Google Scholar
  • 36 Abelleira E, García Falcone MG, Bueno F, Pitoia F. Role of 18F-FDG-PET/CT in patients with differentiated thyroid cancer with biochemical incomplete or indeterminate response to treatment. Endocrinol Diabetes Nutr (Engl Ed) 2020; 67 (08) 517-524
    PubMedSuche in Google Scholar
  • 37 Lu CZ, Cao SS, Wang W, Liu J, Fu N, Lu F. Usefulness of PET/CT in the diagnosis of recurrent or metastasized differentiated thyroid carcinoma. Oncol Lett 2016; 11 (04) 2420-2423
    CrossrefPubMedSuche in Google Scholar
  • 38 Tang X, Shi L, Zhao Z. et al. Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer. Medicine (Baltimore) 2023; 102 (24) e33878
    CrossrefPubMedSuche in Google Scholar
  • 39 Pace L, Klain M, Salvatore B. et al. Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients. Clin Nucl Med 2015; 40 (02) 111-115
    CrossrefPubMedSuche in Google Scholar
  • 40 Salvatore B, Klain M, Nicolai E. et al. Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy. Medicine (Baltimore) 2017; 96 (42) e8344
    CrossrefPubMedSuche in Google Scholar
  • 41 Gaertner FC, Okamoto S, Shiga T. et al. FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake. Clin Nucl Med 2015; 40 (05) 378-383
    CrossrefPubMedSuche in Google Scholar